Appia Bio inks $52m Series A

Appia Bio Inc, a developer of engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients, has raised $52 million in Series A financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this